drugset / Trial / NCT06671444
Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Objective： 1. To evaluate the pharmacokinetics of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment. 2. To evaluate the safety of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment.
Timeline
- Start
- 2024-06-03
- Primary completion
- 2024-10-11
- Completion
- 2024-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FAZAMOREXANT | Small molecule | 20 mg | Oral |